Belzutifan for von Hippel-Lindau Disease-Associated Neoplasms

This research article presents updated results from the LITESPARK-004 study, evaluating the efficacy and safety of belzutifan in treating von Hippel-Lindau disease-associated renal cell carcinoma after 50 months of follow-up. The study involved 61 participants across multiple centers, revealing significant objective response rates and detailing adverse events. Findings support the use of belzutifan as a systemic treatment option for this rare genetic disorder.